Sesen Bio Inc (SESN)

[janeyH]

Item 8.01 – Other Events.

On July 11, 2022, Sesen Bio, Inc. (the “Company”) participated in a Type B Meeting with the U.S. Food and Drug Administration (“FDA”). During the meeting, the Company and the FDA discussed outstanding items related to the Company’s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for Vicineum™ for the treatment of non-muscle invasive bladder cancer.

As the Company works to finalize its evaluation of an additional Phase 3 clinical trial, it will continue the process to review potential strategic alternatives with the goal of maximizing shareholder value.